Daily Archives: May 5, 2011

Recommended Readings: Loren Walensky, M.D., Ph.D.

Posted on by
Reply

Friday Lecture Series

Dissecting the BCL-2 Family Interaction Network with Stapled Peptides:

Mechanistic Insights and Pharmacologic Opportunities

Loren Walensky, M.D., Ph.D., assistant professor, department of pediatrics, Harvard Medical School;

assistant professor, pediatric oncology, Dana-Farber Cancer Institute

May 6, 2011

3:45 p.m.-5:00 p.m. (Refreshments, 3:15 p.m., Abby Lounge)

Caspary Auditorium

Braun, C. R., J. Mintseris, E. Gavathiotis, G. H. Bird, S. P. Gygi, and L. D. Walensky. 2010. Photoreactive stapled BH3 peptides to dissect the BCL-2 family interactome. Chemistry and Biology 17, (12): 1325-1333

Kyoung, J. O., S. Barbuto, K. Pitter, J. Morash, L. D. Walensky, and S. J. Korsmeyer. 2006. A membrane-targeted BID BCL-2 homology 3 peptide is sufficient for high potency activation of BAX in vitro. Journal of Biological Chemistry 281, (48): 36999-37008

Letai, A., M. C. Bassik, L. D. Walensky, M. D. Sorcinelli, S. Weiler, and S. J. Korsmeyer. 2002. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2, (3): 183-192

Parra, M., P. Gascard, L. D. Walensky, J. A. Gimm, S. Blackshaw, N. Chan, Y. Takakuwa, et al. 2000. Molecular and functional characterization of protein 4.1B, a novel member of the protein 4.1 family with high level, focal expression in brain. Journal of Biological Chemistry 275, (5): 3247-3255

Walensky, L. D. 2006. BCL-2 in the crosshairs: Tipping the balance of life and death. Cell death and differentiation 13, (8): 1339-1350

Share

Recommended Readings: Charles Rice Ph.D. Monday May 16 2011

Posted on by
Reply

Monday Lectures

Hepatitis C: New Models and New Insights

Charles Rice  Ph.D.

Professor, Laboratory of Virology and Infectious Disease

Caspary Auditorium   May 16 2011    4 p.m.

 

Recommended Readings

Washburn ML; Bility MT; Zhang LG, et al.  2011.  A humanized mouse model to study Hepatitis C virus infection, immune response, and liver disease.  Gastroenterology.  140(4):1334-1344.

Dring MM; Morrison MH; McSharry BP, et al.  2011.  Innate immune genes synergise to predict increased risk of chronic disease in hepatitis C virus infection.  PNAS.  108(14):5736-5741.

Barnaba V.  2010.  Hepatitis C virus infection: a “liaison a trios” amongst the virus, the host, and chronic low-level inflammation for human survival.   Journal of Hepatology.  53(4):752-761.

Berrueta L; Salmen S.  2010.  Immune tolerance at 50 years from the Nobel Prize in Medicine and Physiology: A perspective as a mechanism of immune response against pathogens.  Investigacion Clinica.  51(2):159-192.  Please request this article from Markus Library.

Walker, CM. 2010.  Adaptive immunity to the hepatitis C virus. Book Series:  Advances in virus research. Volume 78.  Pp. 43-86..  

Murray CL; Rice CM.  2010.  Hepatitis C: an unsuspected drug target.  Nature.  465(7294):42-44.

Chockalingam K; Simeon RL; Rice CM, et al.  2010.  A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle.  PNAS. 107(8):3764-3769.

Rehermann B.  2009.  Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution andcoexistence.  Journal of Clinical investigation.  199(7):1745-1754.

Share